Research programme: VLA-1 inhibitors - Array BioPharma/ICOS CorporationAlternative Names: A-328282.0; VLA-1 antagonists - Array/ICOS
Latest Information Update: 23 Mar 2009
At a glance
- Originator Array BioPharma; ICOS Corporation
- Mechanism of Action Integrin alpha1beta1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 23 Mar 2009 Discontinued for Inflammation in USA (unspecified route)
- 16 Apr 2007 Early research in Inflammation in USA (unspecified route)